Spots Global Cancer Trial Database for Study Evaluating CMD-193 in Advanced Malignant Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study Evaluating CMD-193 in Advanced Malignant Solid Tumors
Official Title: A Phase 1 Dose Escalation Study of CMD-193 in Subjects With Advanced Malignant Tumors.
Study ID: NCT00161642
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to determine the safety, tolerability and maximum tolerated dose of CMD-193. Preliminary information about how a person's body processes CMD-193 and how CMD-193 affects tumors will also be collected.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
, Lebanon, New Hampshire, United States
, Philadelphia, Pennsylvania, United States
, Nashville, Tennessee, United States
Contact Details
Name: Medical Monitor
Affiliation: Wyeth is now a wholly owned subsidiary of Pfizer
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
